SCHEMBL24711515

SCHEMBL24711515

COc1cc(C(=O)Nc2cc(-c3nc4cc(C(C)C)ccc4o3)ccc2C)cc(OC)c1OC

nearest known ligand 0.80

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ TP53 P04637 9/20 0.80
▸ HSD17B10 Q99714 4/20 0.80
▸ SMN1; SMN2 Q16637 3/20 0.80
▸ USP2 O75604 2/20 0.80
▸ NPC1 O15118 1/20 0.80
▸ HTT P42858 1/20 0.80
▸ RAB9A P51151 1/20 0.80
▸ LMNA P02545 2/20 0.65
▸ ALDH1A1 P00352 2/20 0.65
▸ NPSR1 Q6W5P4 2/20 0.65
▸ MEN1 O00255 1/20 0.65
▸ MAPK1 P28482 1/20 0.65
▸ KMT2A Q03164 1/20 0.65
▸ MAPT P10636 10/20 0.64
▸ GAA P10253 1/20 0.59
▸ HPGD P15428 1/20 0.59
▸ KDM4E B2RXH2 1/20 0.54
▸ PTGS2 P35354 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24711202 0.87 MAPT (0.66) TP53HSD17B10SMN1; SMN2USP2NPC1
SCHEMBL24710982 0.85 TP53 (0.75) TP53HSD17B10SMN1; SMN2USP2NPC1
SCHEMBL24711203 0.85 MAPT (0.70) TP53HSD17B10SMN1; SMN2USP2NPC1
SCHEMBL24710830 0.84 MAPT (0.71) TP53HSD17B10SMN1; SMN2USP2NPC1
SCHEMBL24711778 0.83 MAPT (0.68) TP53HSD17B10SMN1; SMN2USP2NPC1
SCHEMBL24711239 0.81 MAPT (0.75) TP53HSD17B10SMN1; SMN2USP2NPC1
SCHEMBL24710856 0.79 THRB (0.70) TP53HSD17B10SMN1; SMN2USP2NPC1
SCHEMBL24710992 0.78 MAPT (1.00) TP53HSD17B10SMN1; SMN2NPC1RAB9A
SCHEMBL24710832 0.77 TP53 (0.66) TP53HSD17B10SMN1; SMN2USP2NPC1
SCHEMBL2624627 0.76 MAPT (0.71) TP53HSD17B10USP2LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220395500-A1 SMALL MOLECULE ACTIVATORS OF INTERFERON REGULATORY FACTOR 3 AND METHODS OF USE THEREOF NEURALEXO, INC. 2022-12-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220395500-A1 SMALL MOLECULE ACTIVATORS OF INTERFERON REGULATORY FACTOR 3 AND METHODS OF USE THEREOF IRF3, IRF2BP2, STAT1 TP53 673/4885HSD17B10 4652/4885SMN1; SMN2 1343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback